KRAS and Patent ductus arteriosus: Preclinical studies demonstrated that KRAS siRNA-engineered iExosomes reduce KRAS expression in patient-derived PDA xenografted mice, resulting in compromised cancerous cell proliferation, enhanced apoptosis, inhibited metastasis, and increased overall survival with no cytotoxic effects [52,53].